Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFB | P00751 | 10/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21879803 | 0.81 | CFB (0.40) | CFBARCRHR1HPGDSKDM4E | |
| SCHEMBL24709786 | 0.80 | CSNK1D (0.34) | — | |
| SCHEMBL15812731 | 0.79 | CSNK1A1 (0.33) | KDM4E | |
| SCHEMBL21263286 | 0.78 | PARP1 (0.34) | KDM4EHSD17B10 | |
| SCHEMBL25054312 | 0.78 | ALDH1A1 (0.38) | AR | |
| SCHEMBL24709841 | 0.78 | XDH (0.38) | KDM4E | |
| SCHEMBL23269563 | 0.76 | KDM4E (0.36) | KDM4ELMNAHSD17B10 | |
| SCHEMBL1116206 | 0.71 | NPSR1 (0.47) | MAPK10LMNA | |
| SCHEMBL1116241 | 0.70 | SRC (0.48) | HPGDSLMNA | |
| SCHEMBL6644614 | 0.69 | AR (0.49) | ARCRHR1HPGDSKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834462-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230022513-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2022261221-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261235-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021076448-A1 | SOMATOSTATIN MODULATORS FOR TREATING PITUITARY ADENOMAS | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20200087318-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022513-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CFB 2569/4885AR 1995/4885CRHR1 32/4885 |
| US-20200087318-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | CFB 2569/4885AR 1995/4885CRHR1 32/4885 |
| US-11834462-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | CFB 2569/4885AR 1995/4885CRHR1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.